Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares traded down 1.4% during trading on Thursday . The stock traded as low as $3.44 and last traded at $3.50, with a volume of 157,885 shares. The stock had previously closed at $3.55.

The company’s market capitalization is $229.83 million. The company has a 50-day moving average of $3.59 and a 200-day moving average of $4.63.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its earnings results on Tuesday, May 10th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.48. The business earned $8.10 million during the quarter, compared to analysts’ expectations of $9.70 million. The business’s revenue was up 84.1% on a year-over-year basis. Equities analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.

In related news, insider Eric Trachtenberg bought 10,000 shares of the stock in a transaction on Monday, May 16th. The shares were purchased at an average price of $3.76 per share, for a total transaction of $37,600.00. Following the acquisition, the insider now owns 144,500 shares in the company, valued at $543,320. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew I. Koven bought 71,500 shares of the stock in a transaction on Thursday, May 12th. The shares were bought at an average price of $3.49 per share, for a total transaction of $249,535.00. Following the acquisition, the insider now owns 1,610,306 shares in the company, valued at approximately $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.